This section highlights FDA-related milestones and regulatory updates for drugs developed by Atossa Genetics (ATOS).
Over the past two years, Atossa Genetics has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as
Z-endoxifen, endoxifen-Z, Endoxifen, and EVANGELINE. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend.
Select a button below to view the list of FDA events for that drug.
Z-endoxifen FDA Regulatory Timeline and Events
Z-endoxifen is a drug developed by Atossa Genetics for the following indication: Breast cancer in the neoadjuvant (prior to surgery) setting.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- Z-endoxifen
- Announced Date:
- May 4, 2026
- Indication:
- Breast cancer in the neoadjuvant (prior to surgery) setting
Announcement
Atossa Therapeutics, Inc announced that the U.S. Food and Drug Administration ("FDA") has granted Rare Pediatric Disease ("RPD") designation to (Z)-endoxifen for the treatment of McCune-Albright Syndrome ("MAS") in females.
AI Summary
Atossa Therapeutics announced the U.S. Food and Drug Administration granted Rare Pediatric Disease (RPD) designation to (Z)-endoxifen for the treatment of McCune-Albright Syndrome (MAS) in females. The designation expands Atossa’s (Z)-endoxifen program into a rare pediatric endocrine disorder. MAS is a rare condition that can cause hormonal and developmental problems in affected girls.
RPD designation may make a drug eligible for a Priority Review Voucher (PRV) if the medicine later wins FDA approval through a qualifying New Drug Application or Biologics License Application and meets statutory criteria. A PRV can speed review of another product and may be used, sold, or transferred, potentially creating value for the sponsor.
Atossa said the designation underscores its commitment to work with clinical and patient communities as it advances (Z)-endoxifen for MAS. The program remains in clinical development and is supported by an expanding intellectual property portfolio.
Read Announcement- Drug:
- Z-endoxifen
- Announced Date:
- October 13, 2025
- Indication:
- Breast cancer in the neoadjuvant (prior to surgery) setting
Announcement
Atossa Therapeutics, Inc. announces key progress in its global intellectual-property strategy for Z-endoxifen, including the issuance of an Israeli patent and continued renewals that reinforce protection for the Company's lead program across major jurisdictions.
AI Summary
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced important progress in its global intellectual-property strategy for Z-endoxifen. The company secured an Israeli patent (No. 304863) on “Methods for Making and Using Endoxifen,” strengthening protection for its lead program. This award reflects filings dating back to U.S. provisional applications from 2017 and 2018.
The Israeli patent covers high-purity, delayed-release oral formulations containing at least 90% Z-endoxifen, with strict impurity limits and defined release profiles in gastric and intestinal environments. It also specifies dose strengths (1–4 mg and 8 mg), pharmacokinetic targets for plasma exposure and steady-state levels, and manufacturing methods that enrich the active Z-isomer through controlled crystallization and solvents.
Alongside the patent grant, Atossa confirmed the renewal of Patent No. 304863 with the Israel Patent Office. This milestone supports the company’s life-cycle management and aligns with its global IP filings. Atossa’s leadership believes these durable patents will safeguard product quality, support future clinical and commercial plans, and create long-term value for shareholders.
Read Announcement- Drug:
- Z-endoxifen
- Announced Date:
- October 6, 2025
- Indication:
- Breast cancer in the neoadjuvant (prior to surgery) setting
Announcement
Atossa Therapeutics, Inc. (announces an amendment to its Phase 2 EVANGELINE study of (Z)-endoxifen in premenopausal women with newly diagnosed early-stage ER+/HER2- breast cancer.
AI Summary
Atossa Therapeutics amended its Phase 2 EVANGELINE study of investigational (Z)-endoxifen in premenopausal women with newly diagnosed early-stage ER+/HER2– breast cancer. The revised, non-registrational design will use short-interval, objective endpoints to speed data readouts and cut future study costs.
The updated plan focuses on Week-4 Ki-67, a marker of tumor cell growth, with a two-stage futility rule in Cohort A to allow early stops if the ≤10% target isn’t met. Cohort B will assess longer-term response. Patient safety monitoring and oversight by the Data Safety Monitoring Committee remain unchanged.
By reducing enrollment from 214 to 40–65 women, Atossa aims to concentrate on critical data for its NDA-enabling package. This amendment is intended to extend the company’s operating runway and direct resources toward planned regulatory activities in 2026.
Read Announcement
Endoxifen-Z FDA Regulatory Timeline and Events
Endoxifen-Z is a drug developed by Atossa Genetics for the following indication: for Breast Cancer.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- endoxifen-Z
- Announced Date:
- March 12, 2026
- Indication:
- for Breast Cancer
Announcement
Atossa Therapeutics, Inc. presented an oral clinical trial update on (Z)-endoxifen at the MDA Clinical & Scientific Conference on March 11, 2026, in Orlando, FL.
AI Summary
Atossa Therapeutics presented an oral clinical trial update on (Z)-endoxifen at the MDA Clinical & Scientific Conference on March 11, 2026, in Orlando, FL. The company highlighted preclinical data showing that (Z)-endoxifen restored muscle performance and reduced markers of muscle damage in mdx5Cv dystrophic mice, a model of Duchenne muscular dystrophy (DMD).
Presenters said the compound appeared to address multiple aspects of DMD pathology, including muscle weakness, structural damage, inflammation and functional decline. These findings support moving (Z)-endoxifen forward in clinical development as a potential new treatment option for DMD patients who still face high unmet needs despite existing therapies.
Atossa noted the program is backed by an expanding global intellectual property portfolio, including several recently issued U.S. patents and additional applications pending worldwide, and included standard forward-looking statements tied to the press release date.
Read Announcement- Drug:
- endoxifen-Z
- Announced Date:
- February 5, 2026
- Indication:
- for Breast Cancer
Announcement
Atossa Therapeutics, Inc today reaffirmed its strong market position around its Duchenne Muscular Dystrophy (DMD) program following yesterday's congressional announcement that it had passed a five-year reauthorization of the Rare Pediatric Disease Priority Review Voucher ("PRV") Program.
AI Summary
Following yesterday's congressional announcement that the Rare Pediatric Disease Priority Review Voucher (PRV) Program was reauthorized for five years, Atossa Therapeutics, Inc. reaffirmed its strong market position around its Duchenne muscular dystrophy (DMD) program. Atossa's (Z)-endoxifen has a Rare Pediatric Disease Designation for neuromuscular diseases and would qualify for a PRV if it receives FDA approval. That designation strengthens Atossa's standing in DMD, a severe neuromuscular disease affecting children and young adults.
Atossa says its (Z)-endoxifen program is supported by a growing global intellectual property portfolio, including multiple recently issued U.S. patents and numerous pending applications worldwide. The company notes the market value of a PRV is variable and past sale amounts may not predict future prices. Forward-looking statements were presented as of the press release date and, except as required by law, the company does not intend to update them.
Read Announcement- Drug:
- endoxifen-Z
- Announced Date:
- January 16, 2026
- Indication:
- for Breast Cancer
Announcement
Atossa Therapeutics, Inc. announced that the U.S. Food and Drug Administration ("FDA") Office of Orphan Products Development ("OOPD") has granted Orphan Drug Designation to (Z)-endoxifen for the treatment of Duchenne muscular dystrophy ("DMD").
AI Summary
Atossa Therapeutics announced that the FDA Office of Orphan Products Development has granted Orphan Drug Designation to (Z)-endoxifen for the treatment of Duchenne muscular dystrophy (DMD). The designation supports Atossa’s push to develop (Z)-endoxifen for this rare pediatric neuromuscular disease and marks an important step as the company advances the program.
Orphan Drug Designation is given to therapies for rare conditions and can offer incentives such as regulatory support and, if the drug later wins approval for the same use, eligibility for a period of market exclusivity. The designation does not shorten development time or guarantee regulatory approval.
DMD is an X-linked, progressive disorder that causes early muscle weakness, loss of walking ability, breathing and heart problems, and often premature death. (Z)-endoxifen is an oral selective estrogen receptor modulator/degrader with multiple mechanisms of interest and a safety and pharmacology profile distinct from tamoxifen; it is not approved for any indication. Atossa says it will continue working with FDA and provide updates as development progresses.
Read Announcement- Drug:
- endoxifen-Z
- Announced Date:
- January 6, 2026
- Indication:
- for Breast Cancer
Announcement
Atossa Therapeutics, Inc. announced that the U.S. Food and Drug Administration ("FDA") issued a "Study May Proceed" letter for the Company's study in metastatic breast cancer which was the subject of a recent investigational new drug application for (Z)-endoxifen.
AI Summary
Atossa Therapeutics announced that the U.S. Food and Drug Administration issued a "Study May Proceed" letter for its investigational new drug study of (Z)-endoxifen in metastatic ER+/HER2- breast cancer. The company called the letter an important regulatory milestone and said it could allow testing of (Z)-endoxifen in tumors that have become resistant to other endocrine therapies. Atossa's CEO noted the drug’s activity, including effects on the oncogenic signaling pathway protein kinase C beta 1 (PKCβ1), may offer a new treatment option and the company looks forward to advancing the clinical study.
(Z)-endoxifen is a potent selective estrogen receptor modulator/degrader (SERM/D) in an oral formulation that Atossa says has a favorable safety profile and pharmacology distinct from tamoxifen, including ER-targeted effects and PKC inhibition. The drug is not approved for any indication and is being developed across multiple clinical settings, supported by a growing intellectual property portfolio.
Read Announcement- Drug:
- endoxifen-Z
- Announced Date:
- December 11, 2025
- Indication:
- for Breast Cancer
Announcement
Atossa Therapeutics, Inc. announced that the U.S. Food and Drug Administration ("FDA") has granted Rare Pediatric Disease ("RPD") designation to (Z)-Endoxifen for the treatment of Duchenne Muscular Dystrophy ("DMD").
AI Summary
Atossa Therapeutics announced the U.S. Food and Drug Administration has granted Rare Pediatric Disease (RPD) designation to (Z)-Endoxifen for treating Duchenne Muscular Dystrophy (DMD). The designation expands Atossa’s (Z)-Endoxifen program into rare pediatric neuromuscular disease and supports its plan to advance the candidate toward clinical testing for boys with DMD.
RPD designation is for drugs addressing serious conditions that mainly affect people under 18. If (Z)-Endoxifen is later approved under the program, Atossa may be eligible for a Priority Review Voucher (PRV) that can speed review of a future application or be sold. Recent disclosed PRV sales have ranged roughly $100–$160 million.
(Z)-Endoxifen is a potent selective estrogen receptor modulator/degrader (SERM/D). Atossa says the drug could offer a broader approach than exon-specific therapies and will follow the RPD regulatory pathway with enhanced FDA interaction as it defines clinical development for DMD.
Read Announcement- Drug:
- endoxifen-Z
- Announced Date:
- December 9, 2025
- Indication:
- for Breast Cancer
Announcement
Atossa Therapeutics, Inc announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 12,479,790 B2, titled, "Methods for Making and Using Endoxifen."
AI Summary
Atossa Therapeutics announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 12,479,790 B2, titled "Methods for Making and Using Endoxifen." The patent, assigned to Atossa, contains 100 claims covering enteric oral formulations of highly pure (Z)-endoxifen free base. It also covers methods of using those compositions to treat hormone-dependent breast disorders and other estrogen-related conditions. In addition, the patent protects specific solid oral dosage forms and stable formulations designed to give therapeutically meaningful and sustained systemic exposure to (Z)-endoxifen.
Atossa says the patent strengthens its endoxifen intellectual property by covering scalable manufacturing processes and key methods of use. The company sees the patent as supporting its plan to develop (Z)-endoxifen across the breast cancer spectrum and in other hormone-driven conditions, helping secure exclusivity while it advances late-stage trials and potential commercialization efforts.
Read Announcement- Drug:
- endoxifen-Z
- Announced Date:
- December 4, 2025
- Indication:
- for Breast Cancer
Announcement
Atossa Therapeutics, Inc. announced the completion of a Type C meeting with the U.S. Food and Drug Administration ("FDA") on November 17, 2025, to review regulatory strategy for advancing (Z)-endoxifen.
AI Summary
Atossa Therapeutics completed a Type C meeting with the U.S. Food and Drug Administration on November 17, 2025, to review regulatory strategy for advancing (Z)-endoxifen. During the meeting, the FDA gave feedback on potential expedited regulatory pathways and development options across metastatic disease, neoadjuvant treatment, and breast cancer risk-reduction settings. The discussion focused on clinical trial design, endpoint selection, and pathways that could support a streamlined registrational approach.
Atossa said the FDA interaction clarified possible routes to speed clinical development and regulatory review, positioning the company to pursue a faster, more focused strategy across multiple breast cancer indications. Planned efforts highlighted after the meeting include dose-ranging work in metastatic breast cancer, continued enrollment and data generation in the Phase 2 EVANGELINE neoadjuvant trial, and a low-dose risk-reduction strategy aimed at lowering mammographic breast density and overall breast cancer risk.
Read Announcement- Drug:
- endoxifen-Z
- Announced Date:
- December 2, 2025
- Indication:
- for Breast Cancer
Announcement
Insilico Medicineand Atossa Therapeutics announce the publication of a joint study evaluating the potential of (Z)-endoxifen for glioblastoma multiforme (GBM).
AI Summary
Insilico Medicine and Atossa Therapeutics published a joint study in Scientific Reports evaluating (Z)-endoxifen as a potential treatment for glioblastoma multiforme (GBM). Using Insilico’s AI-driven PandaOmics platform, researchers screened over 900 cancer indications with multi-omics approaches, transcriptomic integration, single-cell sequencing, pathway and network analysis, and survival modeling. The AI analysis ranked GBM as a top candidate where endoxifen’s known mechanisms could be therapeutically useful.
The study identified more than 1,400 genes shared between GBM tumors and endoxifen-treated cells, predicting reversal of pathways linked to proliferation, inflammation, metabolism, and treatment resistance. Laboratory tests matched predictions: endoxifen reduced GBM cell growth, induced apoptosis, outperformed high‑dose temozolomide in vitro, and showed enhanced effects in combination. In vivo dosing was well tolerated. The authors conclude that (Z)-endoxifen is a promising candidate for GBM and that AI-enabled repurposing can reveal new therapeutic opportunities.
Read Announcement- Drug:
- endoxifen-Z
- Announced Date:
- October 21, 2025
- Indication:
- for Breast Cancer
Announcement
Atossa Therapeutics, Inc. announced that Laura J. Esserman, MD, MBA, Professor of Surgery and Radiology at the University of California, San Francisco and Principal Investigator of RECAST™, will speak at the Early Detection Research Conference in Portland, OR, about the Company's collaborative work in the RECAST platform trial for ductal carcinoma in situ (DCIS), a biologically heterogeneous, non-invasive breast condition that can progress to invasive breast cancer in a subset of patients.
Read Announcement- Drug:
- endoxifen-Z
- Announced Date:
- September 8, 2025
- Indication:
- for Breast Cancer
Announcement
Atossa Therapeutics, Inc. announced today it has requested a Type C meeting with the U.S. Food and Drug Administration (FDA) to discuss a regulatory strategy aimed at accelerating development of low-dose (Z)-endoxifen for breast cancer risk reduction. Atossa is a clinical-stage biopharmaceutical company developing new approaches in breast cancer treatment and risk-reduction, commonly termed prevention of breast cancer.
AI Summary
Atossa Therapeutics, a clinical-stage biopharmaceutical company focused on breast cancer treatment and prevention, has requested a Type C meeting with the U.S. Food and Drug Administration to discuss a regulatory strategy aimed at accelerating development of low-dose (Z)-endoxifen for breast cancer risk reduction. Beginning in June 2025, Atossa engaged a top FDA law firm and senior regulatory experts to review its extensive (Z)-endoxifen data and published literature. The company filed the meeting request and expects an FDA response by year-end 2025. A favorable outcome could shorten approval timelines by years and save tens of millions of dollars in clinical trial costs.
With an estimated 1.6–2.1 million tamoxifen prescriptions filled annually for prevention or adjuvant therapy, there’s a substantial market opportunity. Unlike tamoxifen, (Z)-endoxifen avoids variability from CYP2D6 metabolism, reaches therapeutic levels within hours, and offers a more predictable, faster-acting preventive option for high-risk women.
Read Announcement- Drug:
- endoxifen-Z
- Announced Date:
- July 29, 2025
- Indication:
- for Breast Cancer
Announcement
Atossa Therapeutics, Inc. announced positive written feedback from the U.S. Food and Drug Administration (FDA) regarding the company's proposed dose optimization trial of (Z)-endoxifen for the treatment of estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer.
AI Summary
Atossa Therapeutics announced that the U.S. Food and Drug Administration provided positive written feedback on its planned dose optimization trial of (Z)-endoxifen for ER+ HER2- metastatic breast cancer. The FDA affirmed key parts of the clinical plan, removed the need for a pre-IND virtual meeting, and supported an IND submission targeted for late 2025.
The agency agreed that existing clinical and nonclinical data are enough to start the monotherapy trial, offered guidance on randomization and study design, and backed combining (Z)-endoxifen with approved breast cancer treatments like CDK4/6, PI3K and mTOR inhibitors. FDA also approved the safety data package and the company’s cardiac monitoring plan.
Atossa will soon share details on patient selection, combination therapies, and trial design. With FDA support in hand, the company aims to submit its IND by the fourth quarter of 2025.
Read Announcement- Drug:
- endoxifen-Z
- Announced Date:
- May 14, 2025
- Indication:
- for Breast Cancer
Announcement
Atossa Therapeutics, today reported full results from the Phase 2 Endocrine Optimization Pilot (EOP) sub‑study within the I‑SPY 2 TRIAL evaluating low‑dose oral (Z)‑endoxifen (10 mg daily) as a neoadjuvant treatment in 20 women with stage II/III estrogen‑receptor–positive (ER+), HER2‑negative breast cancer.
AI Summary
Atossa Therapeutics today announced full results from the Phase 2 Endocrine Optimization Pilot (EOP) sub‑study within the I‑SPY 2 Trial. The study tested low‑dose oral (Z)‑endoxifen (10 mg daily) as a neoadjuvant treatment in 20 women with stage II/III estrogen‑receptor–positive, HER2‑negative breast cancer. The trial achieved its feasibility endpoint, with 95% of participants completing at least 75% of the planned dosing. Early signs of treatment effect were observed as the key cancer cell marker Ki‑67 dropped from 10.5% at baseline to 5% by Week 3, with 65% of patients reaching Ki‑67 levels at or below 10%. Additionally, MRI scans showed significant tumor shrinkage, confirming the drug’s anti‑proliferative activity. The low‑dose (Z)‑endoxifen was well tolerated, with mostly mild side effects, paving the way for further studies using higher doses and combination therapies.
Read Announcement
Endoxifen FDA Regulatory Timeline and Events
Endoxifen is a drug developed by Atossa Genetics for the following indication: Breast Cancer.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- Endoxifen
- Announced Date:
- December 11, 2024
- Indication:
- Breast Cancer
Announcement
Atossa Therapeutics, Inc announced full results from its Phase 2 KARISMA-Endoxifen trial conducted at the Karolinska Institute in Stockholm, Sweden.
AI Summary
Atossa Therapeutics, Inc. announced the full results from its Phase 2 KARISMA-Endoxifen trial, which was conducted at the Karolinska Institute in Stockholm, Sweden. The study evaluated low-dose (Z)-endoxifen as a potential preventative therapy for premenopausal women at risk of developing breast cancer. In the trial, 240 premenopausal women were randomized in a double-blind, placebo-controlled study to receive either placebo, 1 mg, or 2 mg of oral (Z)-endoxifen daily for six months. The results showed that the 1 mg dose lowered mammographic breast density by 17.3 percentage points, while the 2 mg dose reduced it by 23.5 percentage points, compared to almost no change in the placebo group. Notably, the 1 mg dose was well-tolerated with no significant differences in adverse events compared to placebo, highlighting its potential as a safe and effective option for breast cancer prevention.
Read Announcement- Drug:
- Endoxifen
- Announced Date:
- July 22, 2024
- Indication:
- Breast Cancer
Announcement
Atossa Therapeutics, Inc. announced that the 12-patient 80mg pharmacokinetic (PK) run-in cohort of the Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) study has fully enrolled.
AI Summary
Atossa Therapeutics, Inc. announced that the 12-patient 80mg pharmacokinetic (PK) run-in cohort for its Phase 2 EVANGELINE study has fully enrolled. This study focuses on pre-menopausal women with Grade 1 or 2 Estrogen Receptor positive (ER+)/Human Epidermal Growth Factor Receptor 2 negative (HER2-) breast cancer. During this initial phase, each patient will receive 80mg of (Z)-endoxifen daily for four weeks. After this period, those participants whose tumors show a reduction, indicated by Ki-67 levels below 10%, will continue the treatment for an additional five months before undergoing surgery.
This milestone is an important step in evaluating the optimal dose and safety profile of (Z)-endoxifen. The study will eventually expand to about 175 patients at up to 25 sites across the United States as the treatment cohort begins once the ideal dosing is confirmed.
Read Announcement- Drug:
- Endoxifen
- Announced Date:
- June 28, 2024
- Indication:
- Breast Cancer
Announcement
Atossa Therapeutics, Inc. announced protocol changes in the previously initiated study to evaluate Atossa's proprietary (Z)-endoxifen in combination with abemaciclib (VERZENIO®), a cyclin-dependent kinase (CDK) 4/6 inhibitor marketed by Eli Lilly and Company.
AI Summary
Atossa Therapeutics, Inc. announced important protocol changes in its study evaluating the combination of its proprietary (Z)-endoxifen with abemaciclib (VERZENIO®). This study focuses on neoadjuvant treatment for women with newly diagnosed ER+/HER2- breast cancer. Based on promising safety, efficacy, and pharmacokinetic data from the ongoing Phase 2 EVANGELINE study, the (Z)-endoxifen dose has been increased from 40 mg to 80 mg once daily. This change aims to achieve optimal drug concentrations to target PKCβ1 inhibition and further enhance the antitumor effects of (Z)-endoxifen.
The updated study protocol will enroll approximately 80 participants across two cohorts of 40 each. One cohort will include premenopausal women receiving ovarian function suppression, allowing for a direct comparison of safety and efficacy between treatment groups. These modifications are expected to deepen understanding of the combination’s safety profile and clinical benefits, helping to guide future conversations with regulators and potential partners.
Read Announcement
EVANGELINE FDA Regulatory Events
EVANGELINE is a drug developed by Atossa Genetics for the following indication: for premenopausal women with estrogen receptor-positive (ER+)/HER2-negative breast cancer.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- EVANGELINE
- Announced Date:
- December 10, 2024
- Indication:
- for premenopausal women with estrogen receptor-positive (ER+)/HER2-negative breast cancer.
Announcement
Atossa Therapeutics, Inc. announced that three posters involving pharmacokinetic and tolerability data from the Phase 2 EVANGELINE trial will be presented at the 2024 San Antonio Breast Cancer Symposium (SABCS 2024).
AI Summary
Atossa Therapeutics, Inc. announced that three posters from their Phase 2 EVANGELINE trial will be showcased at the 2024 San Antonio Breast Cancer Symposium (SABCS 2024). The posters present new pharmacokinetic and tolerability data for (Z)-endoxifen as a neoadjuvant treatment for premenopausal women with estrogen receptor-positive, HER2-negative breast cancer.
One poster details the pharmacokinetic run-in phase where (Z)-endoxifen doses of 40 mg and 80 mg—with or without goserelin—were evaluated, showing promising plasma and tissue concentration levels. Another focuses on patient-reported outcomes and quality of life measures, demonstrating that (Z)-endoxifen is generally well-tolerated with mostly low-grade side effects. The third poster outlines the design and rationale for a randomized trial comparing (Z)-endoxifen plus ovarian function suppression to exemestane plus ovarian function suppression. This data highlights a clear plan for further advancing treatment options in breast cancer.
Read Announcement
